BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR
    4.
    发明公开
    BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR 审中-公开
    利用BTK抑制剂预测DLBCL对治疗反应的生物标志物

    公开(公告)号:EP3185870A1

    公开(公告)日:2017-07-05

    申请号:EP15828160.0

    申请日:2015-07-31

    申请人: Pharmacyclics LLC

    IPC分类号: A61K31/519

    摘要: Disclosed herein, are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes (e.g. EP300, MLL2, BCL-2, RB1, LRP1B, PIM1, TSC2, TNFRSF11A, SMAD4, PAX5, CARD11, ACTG2, LOR, GAPT, CCND2, SELL, GEN1, HDAC9, CD79B, MYD88, and ROS1) or biomarker gene expression levels for stratifying a patient having a hematological malignancy such as DLBCL for treatment, and administering a TEC inhibitor to selected patients. Also disclosed herein are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes, or biomarker gene expression levels for monitoring a patient during treatment of a hematological malignancy such as DLBCL or FL or for optimizing a treatment regimen with a TEC inhibitor.

    摘要翻译: 生物标记基因(例如EP300,MLL2,BCL-2,RB1,LRP1B,PIM1,TSC2,TNFRSF11A,SMAD4,PAX5,CARD11,ACTG2,LOR等)的方法,系统,组合物,阵列和试剂盒 GAPT,CCND2,SELL,GEN1,HDAC9,CD79B,MYD88和ROS1)或生物标志物基因表达水平,用于分层患有血液恶性肿瘤如DLBCL的患者进行治疗,并对选定的患者施用TEC抑制剂。 本文还公开了用于在治疗血液恶性肿瘤如DLBCL或FL期间监测患者的生物标志物,生物标志物基因或生物标志物基因表达水平或用TEC优化治疗方案的方法,系统,组合物,阵列和试剂盒 抑制剂。